Introduction {#S1}
============

Acquisition of migratory and invasive capabilities by cancer cells at the primary site is the first step in tumor metastasis ([@R8]). This process resembles epithelial-to-mesenchymal transition (EMT), a highly conserved cellular program in embryonic development. During EMT, epithelial cells lose polarity and gain motility through downregulation of epithelial markers, disruption of the cadherin/catenin adhesion complex and re-expression of mesenchymal molecules, which are necessary for invasion and metastasis. Although demonstrating this potentially rapid and transient process *in vivo* has been difficult, and data linking this process to tumor progression are limited and controversial, mounting experimental and clinical evidence, however, supports a crucial role for EMT in cancer metastasis. A number of EMT-related factors and pathways, such as Snail, wnt/β-catenin and hedgehog signaling, have been shown to be shared by embryonic development and tumor progression. The EMT concept, therefore, provides valuable insight into molecular and cellular mechanisms controlling metastasis ([@R38]).

Metastatic cancer cells are characterized by high motility and invasiveness ([@R48]). Efficient migration and invasion require cancer cells to establish and maintain defined morphologic features, often with lost cell polarity. While stabilization of the actin cytoskeleton is important to the maintenance of an epithelial phenotype, dynamic remodeling of the actin network is crucial for invasive cancer cells to leave the primary tumor, invade through the basement membrane, and extravasate to establish metastases at distant organs. However, cell signaling pathways involved in the regulation of cell-cell adhesion and the actin cytoskeleton network in metastatic cancer cells have not been fully elucidated ([@R23]).

EPLIN (epithelial protein lost in neoplasm; or LIM domain and actin binding 1, LIMA-1) was initially identified as an actin-binding protein that was preferentially expressed in human epithelia but frequently lost in cancerous cells ([@R25], [@R36]). Two EPLIN isoforms, the 600-residue EPLIN-α and 759-residue EPLIN-β, differ only at the 5' end, where an alternative RNA processing event extends the reading frame of EPLIN-β by an additional 160 amino acids (aa) ([@R4], [@R25]). EPLIN contains a central located LIM domain that may allow EPLIN to dimerize with itself or associate with other proteins. Both the N- and C-termini of EPLIN bind actin to promote the parallel formation of filamentous actin polymer (F-actin) structures by cross-linking and bundling actin filaments. EPLIN also inhibits the Arp2/3-mediated nucleation of actin filaments and suppresses F-actin depolymerization ([@R26]). A recent study demonstrated EPLIN as a key molecule linking the cadherin--catenin complex to F-actin ([@R1]), which may simultaneously stabilize the adhesion belt formed by the adherens junctions and a bundle of cortical actin filaments near the apical surface of epithelial cells ([@R30]). The direct interaction between EPLIN and α-catenin *via* both the N- and C-terminal regions is indispensable for the formation of apical actin belt. These observations indicate that EPLIN may be critical to the maintenance of epithelial phenotypes. Nonetheless, investigation into the role of EPLIN in tumor progression remains rudimentary. A recent report inversely correlated EPLIN expression with the aggressiveness and clinical outcome of breast cancer ([@R10]).

By conducting quantitative proteomics using an experimental model of human PCa metastasis, we observed strikingly decreased EPLIN expression upon EMT. Biochemical and functional analyses indicated that EPLIN is a negative regulator of EMT and invasiveness in PCa cells. Importantly, EPLIN downregulation correlated with lymph node metastases in PCa and other solid tumors. These studies reveal a novel role of EPLIN in the regulation of EMT and tumor metastasis.

Results {#S2}
=======

Quantitative proteomic analysis of protein expression profile in a PCa EMT model {#S3}
--------------------------------------------------------------------------------

Previously we reported the ARCaP (androgen refractory cancer of the prostate) cell lineage as an experimental model that resembles the classical descriptions of EMT and closely mimics the clinical pathophysiology of PCa metastasis ([@R47], [@R53]). The more epithelial ARCaP~E~ and more mesenchymal ARCaP~M~ cells are lineage-related, defined as genetically identical, but behaviorally and phenotypically different. ARCaP~E~ cells display typical cobblestone morphology and have a relatively low bone metastatic propensity (12.5%) after intracardiac injection in immunocompromised mice, whereas ARCaP~M~ cells have spindle-shaped fibroblastic morphology associated with increased expression of vimentin and reduced expression of epithelial markers. Importantly, the switch in morphology and gene expression in ARCaP~M~ cells is associated with high metastatic propensity to skeleton (100%) and soft tissues (33% to adrenal gland). We and others reported that EMT in ARCaP~E~ cells can be induced by soluble growth factors *in vitro* or by direct interaction with mouse skeleton *in situ* ([@R9], [@R53]).

To gain an unbiased insight into the molecular mechanisms underlying PCa EMT, we used an internally standardized gel-free quantitative proteomic technique, cleavable Isotope-Coded Affinity Tag (cICAT) analysis using stable isotope tags (^12^C and ^13^C), in combination with 2-dimensional liquid chromatography-tandem mass spectrometry (2-D LC-MS/MS) ([@R14], [@R15]), to compare protein expression patterns in the total lysates of ARCaP~E~ and ARCaP~M~ cells. We identified 343 unique proteins as expressed in both ARCaP~E~ and ARCaP~M~ cells when a ProtScore threshold of 1.3 was used (corresponding to \> 95% protein confidence) ([Table 1A](#T1){ref-type="table"}). Among them, 76 proteins showed differential expression between the cell lines that was considered statistically significant with a *p*-value of less than 0.05: 31 proteins were found to be increased (≥1.20 fold) and 45 proteins were found to be downregulated (≤0.85 fold) in ARCaP~M~ cells ([Table 1B](#T1){ref-type="table"}). These proteins had diverse molecular functions, including cell structure and motility, cell communication, DNA binding and gene expression, metabolism, and signal transduction ([Figure S1](#SD1){ref-type="supplementary-material"}). In agreement with our previous reports ([@R47], [@R53]), proteomics validated increased expression of mesenchymal marker (vimentin) and decreased expression of epithelial markers (cytokeratin-8 and -18) in ARCaP~M~ cells.

EPLIN downregulation is associated with EMT in the experimental models of PCa {#S4}
-----------------------------------------------------------------------------

Intriguingly, a striking downregulation of EPLIN-β (by 4.5-fold, [Table 1B](#T1){ref-type="table"}) was observed in ARCaP~M~ cells. Western blotting ([Figure 1A](#F1){ref-type="fig"}, left panel) and immunocytochemical ([Figure 1A](#F1){ref-type="fig"}, right panel, top) analyses confirmed that both EPLIN-β and -α isoforms were abundantly expressed in ARCaP~E~ cells and reduced significantly in ARCaP~M~ cells. Consistently, immunohistochemical (IHC) analysis showed that EPLIN was substantially expressed in ARCaP~E~ tumor subcutaneously inoculated in athymic nude mice, but significantly reduced in ARCaP~M~ tumor ([Figure 1A](#F1){ref-type="fig"}, right panel, bottom). These data indicated that EPLIN downregulation correlated with increased *in vivo* metastatic potential in the ARCaP EMT model. Supporting this notion, a similar association between EPLIN expression and invasive phenotypes was observed in other experimental models of PCa and squamous cell carcinoma of the head and neck (SCCHN) ([Figure S2](#SD1){ref-type="supplementary-material"}). It was interesting to note that the two EPLIN isoforms were differentially expressed in a cell context-dependent manner: EPLIN-α is prevalently presented in SCCHN cells ([Figure S2B](#SD1){ref-type="supplementary-material"}), whereas EPLIN-β is the major isoform in LNCaP, C4-2 and MCF-7 cells ([Figure S3A, S3B](#SD1){ref-type="supplementary-material"}). In comparison, EPLIN-α and -β appeared to be equally expressed by ARCaP and PC3 cells ([Figures 1A](#F1){ref-type="fig"}, [S3A](#SD1){ref-type="supplementary-material"}).

EPLIN depletion promotes EMT and induces the remodeling of the actin cytoskeleton {#S5}
---------------------------------------------------------------------------------

To investigate the role of EPLIN in the regulation of EMT, ARCaP~E~ cells were transiently transfected with an EPLIN siRNA that effectively inhibited expression of both EPLIN-β and -α isoforms ([Figure 1B](#F1){ref-type="fig"}, left panel). ARCaP~E~ cells expressing control siRNA exhibited a cobblestone-like morphology similar to parent ARCaP~E~ cells, with tight cell-cell contacts in monolayer cultures. EPLIN depletion in ARCaP~E~ cells led to loss of cell-cell contacts and the emergence of spindle-shaped and mesenchymal-like morphology ([Figure 1B](#F1){ref-type="fig"}, right panel), indicating the occurrence of EMT in these cells.

Previous studies have demonstrated an important function of EPLIN in stabilizing the actin cytoskeleton ([@R26], [@R36]). To investigate whether EPLIN depletion in PCa cells was associated with the reorganization of the actin cytoskeleton, immunofluorescent confocal microscopy was performed ([Figures 1C](#F1){ref-type="fig"}, [S4](#SD1){ref-type="supplementary-material"}). In ARCaP~E~ cells expressing control siRNA, EPLIN largely co-localized with actin stress fibers as revealed by phalloidin staining. EPLIN was also associated with circumferential fibers that were characterized by a circular arrangement along the adhesion belt and bundles of actin filaments linked to the plasma membrane. EPLIN siRNA transfection reduced EPLIN that co-localized with the circumferential fibers and induced actin remodeling, which was manifested as the disassembly of cellular stress fibers, a concomitant gain of actin foci and formation of prominent membrane ruffles. These data indicated that upon EPLIN depletion, PCa cells may undergo active reorganization of the actin cytoskeleton, which could contribute to increased migratory and invasive capabilities ([@R50]).

EPLIN depletion enhances *in vitro* migration and invasion {#S6}
----------------------------------------------------------

We further investigated whether the morphological change of ARCaP~E~ cells was associated with invasive behavior *in vitro*. Indeed, EPLIN depletion significantly increased the migratory capability of ARCaP~E~ cells in a wound-healing assay ([Figure 1D](#F1){ref-type="fig"}, upper panel). The infiltration of ARCaP~E~ cells through Matrigel in a modified Boyden chamber was also remarkably increased (by \~ 2-fold) following EPLIN siRNA transfection ([Figure 1D](#F1){ref-type="fig"}, bottom panel). Such effects of EPLIN siRNA transfection were also observed in other PCa (LNCaP, PC3) and human breast cancer (MCF-7) cells ([Figure S3B-S3E](#SD1){ref-type="supplementary-material"}). These data suggest that EPLIN downregulation could significantly enhance the *in vitro* invasive capabilities in epithelial cancer cells.

EPLIN depletion suppresses E-cadherin, activates β-catenin signaling and enhances chemoresistance {#S7}
-------------------------------------------------------------------------------------------------

We established eight ARCaP~E~ sublines that respectively expressed four different 29-mer EPLIN short-hairpin RNAs (shRNAs) ([Table S5](#SD1){ref-type="supplementary-material"}). These sublines exhibited similar morphological, biochemical and behavior characteristics. One of such ARCaP~E~ sublines (ARCaP~E~-shRNA clone \#102) expressing a shRNA sequence of 5\'-TAATAGACGGCAATGGACCTCACTATCAT-3\' was used as the representative. Consistently, ARCaP~E~-shRNA cells exhibited a typical mesenchymal morphology compared to epithelial-like control cells (ARCaP~E~-pRS), indicating the occurrence of EMT upon EPLIN depletion ([Figure 2A](#F2){ref-type="fig"}). Biochemical analyses found that EPLIN inhibition led to decreased E-cadherin, increased vimentin, nuclear translocation of β-catenin and activation of TCF reporter ([Figure 2B](#F2){ref-type="fig"}). Confocal microscopy further demonstrated that shRNA expression resulted in downregulation of E-cadherin on plasma membrane, disassembly of adherens junctions and structurally distinct actin remodeling in PCa cells ([Figure 2C](#F2){ref-type="fig"}). Interestingly, it appeared that EPLIN depletion slightly inhibited proliferation of ARCaP~E~ cells ([Figure 2D](#F2){ref-type="fig"}), which was associated with an arrested cell cycle progression at the G0/G1 and G2 phases ([Figure 2E](#F2){ref-type="fig"}). On the other hand, however, EPLIN depletion significantly enhanced cell resistance to the treatment of docetaxel and Doxorubicin (by \~8-fold and \~4.4-fold, respectively) ([Figure 2F](#F2){ref-type="fig"}). These results indicated an important role of EPLIN in the regulation of EMT, actin dynamics, proliferation and survival in PCa cells.

EPLIN affects a subset of genes involved in EMT and invasion {#S8}
------------------------------------------------------------

To identify genes that are potentially affected by EPLIN, we analyzed the transcriptome of ARCaP~E~-shRNA cells and control cells. Microarray analysis found that there were 1026 genes significantly upregulated and 828 genes significantly downregulated in ARCaP~E~-shRNA cells ([Figure 3A](#F3){ref-type="fig"}), which could be categorized into different function clusters ([Tables S2 and S3](#SD1){ref-type="supplementary-material"}), including those involved in the regulation of EMT, Wnt/β-catenin signaling, actin cytoskeleton, invasion and metastasis, adhesion and extracellular matrix remodeling, and growth factor signaling ([Figure 3B](#F3){ref-type="fig"}; [Tables S3 and S4](#SD1){ref-type="supplementary-material"}). Several approaches were used to validate the differential expression of selected putative EPLIN target genes. Reverse transcription-PCR (RT-PCR) assays ([Figure 3C](#F3){ref-type="fig"}, left panel) demonstrated increased expression of versican, matrix metalloproteinase-7 (MMP-7), Bcl-2A, fibroblast growth factor 5 (FGF5), and downregulation of inhibitor of differentiation 2 (ID2), myosin light chain kinase (MYLK), and insulin-like growth factor-binding protein-3 (IGFBP-3) in ARCaP~E~-shRNA cells. Western blot analyses ([Figure 3C](#F3){ref-type="fig"}, right panel) confirmed downregulation of IGFBP-3 at protein level, and showed that EPLIN depletion increased expression of cAMP-responsive element-binding protein (CREB) and myeloid cell leukemia-1 (Mcl-1) whose upregulation has been associated with clinical PCa metastasis ([@R46], [@R52]). EPLIN depletion significantly increased expression of zinc finger E-box-binding homeobox 1 (ZEB1), a potent EMT activator that transcriptionally suppresses E-cadherin expression ([@R43]), whereas it inhibited Krueppel-like factor (KLF) 5, a zinc finger transcription factor implicated in PCa progression ([@R6]). Consistently, increased presence of ZEB1 and reduced expression of KLF5 in the nucleus of ARCaP~E~-shRNA cells were observed. Expression of Slug and Twist, two master regulators of EMT, was not affected by EPLIN depletion in PCa cells. Zymogram assay ([Figure 3D](#F3){ref-type="fig"}) showed that expression of activated MMP-27 was significantly increased upon EPLIN silencing. EPLIN depletion also resulted in a remarkable increase (\~5.6-fold) in the proportion of ARCaP~E~ cells carrying the CD44^high^/CD24^negative^ marker profile associated with cancer stem cell (CSC) subpopulation ([@R16]) ([Figure 3E](#F3){ref-type="fig"}). Interestingly, EPLIN shRNA suppressed expression of several microRNAs (miRNAs), including miR-205 and two miR-200 family members (miR-200b and miR-429) ([Figure 3F](#F3){ref-type="fig"}), whose downregulation is thought to be the essential feature of EMT and acquisition of CSC properties ([@R19]). These data indicate that EPLIN downregulation may coordinately activate multiple pro-EMT programs in PCa cells.

EPLIN downregulation is associated with lymph node metastasis in PCa, breast cancer, colon cancer and SCCHN {#S9}
-----------------------------------------------------------------------------------------------------------

We searched two global cancer transcriptome databases, i.e., the Gene Expression Omnibus (GEO) and ONCOMINE, for the expression pattern of EPLIN in a number of epithelial cancers. Analyses on four independent sets of microarray data on clinical PCa ([@R3], [@R20], [@R41], [@R51]) revealed that EPLIN transcripts were expressed at a similar level in primary tumors and normal prostatic tissues, but were remarkably reduced in metastatic tumors ([Figure 4A](#F4){ref-type="fig"}). We examined the IHC staining of EPLIN in matched pairs of PCa tissue specimens from primary PCa and lymph node metastases. As shown in [Figure 4B](#F4){ref-type="fig"}, EPLIN expression was significantly reduced in lymph node metastases.

Analyses of the ONCOMINE database found that metastatic colon cancer expresses significantly lower levels of EPLIN transcripts compared to primary tumors ([Figure 5A](#F5){ref-type="fig"}). We examined IHC expression of EPLIN in a human colorectal cancer tissue microarray consisting of matched pairs of primary tumors and lymph node metastases. [Figure 5B](#F5){ref-type="fig"} shows that EPLIN expression was significantly decreased in lymph node metastatic tumors. Similarly, EPLIN immunointensity was markedly reduced in breast cancer lymph node metastases compared to their matched primary tumors ([Figure 5C](#F5){ref-type="fig"}). We finally evaluated IHC expression of EPLIN in 10 pairs of tissue specimens from primary and lymph node metastatic SCCHN. EPLIN expression was also decreased in lymph node metastases ([Figure 5D](#F5){ref-type="fig"}). Collectively, these observations suggested that EPLIN downregulation may be an indicator of clinical metastasis in PCa and several other epithelial cancers.

Discussion {#S10}
==========

In this study, a quantitative proteomics characterized a remarkable downregulation of EPLIN upon EMT in an experimental model of PCa metastasis. Biochemical and functional evidence revealed that EPLIN is a negative regulator of EMT and invasiveness in PCa cells. EPLIN downregulation was found to significantly disrupt epithelial structures, induce actin cytoskeleton remodeling, affect specific gene expression profiles and activate a pro-EMT program. Importantly, using human tumor specimens as the "gold standard", an inverse correlation between EPLIN expression and clinical lymph node metastasis was observed in a variety of solid tumors. These studies elucidate a causal role of EPLIN in EMT and support its new function as a tumor metastasis suppressor ([Figure 6](#F6){ref-type="fig"}).

Emerging proteomic techniques offer robust and unbiased approaches for molecular profiling of the complex metastatic process, including EMT, at the protein level ([@R41]). However, to date only a limited number of proteomic studies were reported in EMT models of human cancer ([@R24]). In this report, we utilized a quantitative proteomic approach, i.e., cICAT in combination with 2-D LC-MS/MS, to characterize protein profile in a novel model for PCa EMT and metastasis. A panel of 76 proteins were found to be significantly altered in the epithelial-like and lowinvasive ARCaP~E~ cells and the mesenchymal-like and highly metastatic ARCaP~M~ cells. Of those, several have been identified to be associated with EMT and metastasis in previous proteomic studies, including increased expression of vimentin, tropomyosin and heat-shock protein β-1 (HSP-β1), and reduced expression of cytokeratin-8, -18 and 14-3-3ε ([@R12], [@R13], [@R21], [@R42], [@R44]). We also observed a concurrent upregulation of S100A10 and its annexin A2 ligand in ARCaP~M~ cells, which is interesting since activation of the S100A10/Annexin A2 signaling has been associated with plasminogen activation and increased tumor invasion and metastasis ([@R18], [@R28]). These results validated the application of quantitative proteomics in identifying key factors implicated in EMT and the acquisition of invasiveness in PCa cells.

At the cellular levels, EMT is characterized by the disappearance of the apical-basal polarity in epithelial cells. Remodeling of the actin cytoskeleton is a prerequisite for the acquisition of migratory and invasive capabilities during this process ([@R23], [@R48], [@R49]). Our proteomic analysis identified a functional group of proteins that have been implicated in the regulation of actin dynamics and cellular structure ([Figure S1](#SD1){ref-type="supplementary-material"}), which includes 6 proteins upregulated (vimentin, keratin II, tropomysin, profilin 1, HSP-β1, and actin-α) and 8 proteins downregulated (LIMA1 or EPLIN, S100A4, echinoderm microtubule associated protein like 5, lamin A/C, matrin-3, tubulin-β2C, cytokeratin-18 and -8) in ARCaP~M~ cells. Among them, EPLIN has been demonstrated as an indispensible component of the core cell polarity complexes, linking the cadherin-- catenin complex to the actin cytoskeleton and actively stabilizes the actin bundles ([@R1], [@R26], [@R36]). Mechanistic studies in non-cancerous (such as NIH3T3) and cancerous (such as MCF-7) cells indicated that both EPLIN isoforms are capable of suppressing F-actin depolymerization and enhancing the bundling of actin filaments through an Arp2/3-mediated mechanism. Downregulation of EPLIN, therefore, may result in cytoskeletal reorganization due to a loss of stability of mature actin filament structure and facilitated turnover of filaments in epithelial cancer cells. Indeed, as revealed by confocal microscopy, EPLIN depletion in ARCaP~E~ cells significantly reduced cellular actin stress fibers and promoted the formation of more dynamic actin filament structures such as membrane ruffling, which may contribute to increased motility of PCa cells. Furthermore, we showed that EPLIN depletion in PCa cells could directly facilitate disassembly of the apical adherens junctions-actin machinery and redistribution of the components of the cadherin-catenin complex, thereby substantially perturbing actin dynamics. These structural alterations may promote transition to mesenchymal morphology and enhance the plasticity and migratory capabilities of epithelial cancer cells ([@R48]) ([Figure 6](#F6){ref-type="fig"}).

Accumulating evidence support that actin and actin-associated proteins are indispensible components of the regulatory machinery of eukaryotic gene transcription, for example, involving in the modulation of RNA polymerase II-dependent transcription and facilitating RNA polymerase I transcription and possibly downstream events during ribosomal RNA biogenesis ([@R29], [@R34]). EPLIN dysregulation may have a remarkable influence on the dynamics of cytoskeleton and its interplay with nuclear architecture, thereby regulating global gene expression. In fact, it has been shown that EPLIN is required for the local accumulation of key cytokinesis proteins at the cleavage furrow during ingression, which is critical to cytokinesis and genomic stability. EPLIN depletion in Hela cells results in cytokinesis failure and formation of multinucleation and aneuploidy ([@R5]). In this study, we identified approximately 1,800 genes that were significantly affected by EPLIN depletion in PCa cells. Among them, some have been implicated in the regulation of EMT and tumor metastasis, for instance, ZEB1 ([@R33], [@R43]), IGFBP-3 ([@R31]), versican ([@R32], [@R37]) and MMPs ([@R11]). Notably, EPLIN depletion in several PCa and breast cancer cells resulted in downregulation of E-cadherin ([Figures 2B](#F2){ref-type="fig"}, [S3B](#SD1){ref-type="supplementary-material"}), a hallmark of EMT and acquired invasiveness in most solid tumors. These interesting findings suggest that EPLIN dysregulation could profoundly affect gene expression at transcriptional levels, which may be an underlying mechanism for EPLIN regulation of EMT.

Loss of expression or function of tumor metastasis suppressors is requisite for the development of local invasion and distant metastases ([@R35]). Previous studies have described several potential metastasis suppressor genes in PCa ([@R39], [@R45]). EPLIN was initially identified as an epithelial protein that is abundantly expressed in normal epithelia but significantly downregulated at mRNA level in a limited number of cancerous cells ([@R25]). This expression profile suggested that EPLIN may function as a suppressor of tumorigenesis in epithelial cancers. Nonetheless, the role and clinical significance of EPLIN during tumor progression remain largely unknown. Our data presented here demonstrated that EPLIN protein is substantially expressed by most low-invasive epithelial cancer cells examined, but significantly decreased in those with high invasive capabilities ([Figures 1A](#F1){ref-type="fig"} and [S2](#SD1){ref-type="supplementary-material"}), implying the involvement of EPLIN in tumor invasion and metastasis. Biochemical and functional analyses further uncovered the function of EPLIN in the maintenance of epithelial phenotypes in low-invasive PCa cells, and a causal role of EPLIN downregulation in promoting EMT and conferring invasiveness, including enhanced migratory and invasive behaviors and resistance to chemotherapy agents. Interestingly, EPLIN depletion resulted in delayed cell cycles and suppressed *in vitro* proliferation, an effect that has been observed when overexpressing certain pro-metastasis genes (such as Snail, Slug) in PCa cells ([@R7], [@R22], [@R27]), suggesting a complicated role of EPLIN in the regulation of PCa cell proliferation and differentiation.

To explore the clinical significance of EPLIN in human cancers, we analyzed the expression profile of EPLIN based on published microarray data. In both PCa and colorectal cancer specimens, EPLIN transcripts were found to be reduced in primary tumors and further decreased in metastatic disease. These observations argue against a simple role of EPLIN as a tumor suppressor, and suggest a new function of EPLIN in late stages of tumor progression in addition to tumorigenesis ([@R10], [@R25]). Indeed, EPLIN protein could be detected at relatively high levels in primary PCa, breast cancer, colorectal cancer and SCCHN, but was significantly reduced in their matched lymph node metastases. Although the numbers of tissue specimens included in this study are limited due to the extreme difficulty of obtaining paired tumor samples from primary and metastatic human cancers, our data clearly demonstrate that EPLIN downregulation could be an indicator of tumor metastasis in a variety of epithelial cancers.

Materials and Methods {#S11}
=====================

Proteomic Analysis {#S12}
------------------

Quantitative proteomic analysis was performed at Emory University Microchemical and Proteomics Facility. Total proteins from ARCaP~E~ and ARCaP~M~ cells were prepared in the absence of proteinase inhibitors by trichloroacetic acid precipitation and resuspended in denaturing buffer. cICAT analysis, in combination with liquid 2-dimensional liquid chromatography-tandem mass spectrometry, was performed as described previously ([@R14], [@R15]). Briefly, the ARCaP~E~ and ARCaP~M~ samples were separately labeled with light and heavy reagent, mixed in equal total protein ratio, and digested overnight with trypsin. The peptides were then desalted using a strong cation-exchange cartridge, and the cICAT-modified, cysteine-containing peptides were enriched/purified using a monomeric avidin column (Applied Biosystems). The biotin tag was cleaved off by treatment with trifluoroacetic acid and the sample was dried and reconstituted in 10% formic acid. A portion of the sample was analyzed using an Ultimate 3000 nanoHPLC system (Dionex, Sunnyvale, CA) using a Vydac C18 silica column interfaced to a QSTAR XL mass spectrometer (Applied Biosystems, CA). The MS/MS data from each salt cut were combined and processed by ProteinPilot software (Applied Biosystems, Carlsbad, CA) for protein identification and quantification. Only proteins with a ProtScore \>1.0 (Confidence Interval \>85%) were considered. Proteins were considered differentially expressed if multiple peptides generated concordant cICAT ratios in both analyses. Proteins were grouped into functional categories using the UniProt Knowledgebase (UniProtKB).

Microarray Analysis {#S13}
-------------------

A reference standard RNA for use in two-color oligo arrays was prepared as described previously ([@R2]). Total RNA from triplicate preparations of control and knockdown samples as well as reference total RNA samples were amplified and hybridized to Agilent 44K whole human genome expression oligonucleotide microarray slides as previously described ([@R17]). Spots of poor quality or average intensity levels \<300 were removed from further analysis. The Statistical Analysis of Microarray (SAM) program ([@R40]) was used to analyze expression differences between control and knockdown groups using unpaired, two-sample *t* tests.

Immunohistochemical Analysis {#S14}
----------------------------

Human PCa tissue specimens were obtained from Emory University Hospital Department of Pathology. Human SCCHN tissue specimens were obtained from the Pathology Core of the Emory University Head and Neck Cancer Specialized Programs of Research Excellence (SPORE). Human colorectal cancer and breast cancer tissue microarrays were purchased from US BioMax, Inc (Rockville, MD). IHC staining of EPLIN was performed as described previously ([@R46]) using a rabbit anti-EPLIN antibody (NB100-2305, Novus Biologicals, LLC, Littleton, CO) at a dilution of 1:50.

Statistical Analysis {#S15}
--------------------

Significance levels for comparisons of protein expression in tumor tissue specimens were calculated by using the 2-sample *t* test. Treatment effects were evaluated using a two-sided Student\'s *t* test. All data represent three or more experiments. Errors are S.E. values of averaged results, and values of *p* ≤ 0.05 were taken as a significant difference between means.

Supplementary Material {#SM}
======================

We thank Dr. Jin-Tang Dong for critical reading of the manuscript, and Dr. Anthea Hammond for editorial assistance. This work was supported by Department of Defense PC060566, American Cancer Society RSG-10-140-01, Georgia Cancer Coalition Cancer Research Award, Kennedy Seed Grant, Emory University Research Committee Award, Winship MPB Seed Grant (D.W), National Cancer Institute grants P01 CA98912, R01 CA122602, and Department of Defense PC060866 (L.W.K. C), Georgia Cancer Coalition Distinguished Scholar Grant (O.K), and National Cancer Institute grant 1R43CA141870 (Y.A. W).

Supplemental Information

Supplemental Information includes Supplemental Materials and Methods, four Supplemental Figures, eight Supplemental Tables and Supplemental References.

![EPLIN depletion promotes EMT and enhances *in vitro* migration and invasion\
(A) Expression of EPLIN in ARCaP cells and xenograft tumors. Left panel: Western blot analysis of EPLIN and E-cadherin in ARCaP~E~ and ARCaP~M~ cells. Right panel: immunocytochemical and immunohistochemical staining of EPLIN expression in ARCaP cells (top) and subcutaneous tumor tissues (bottom). (B) Left panel: effects of EPLIN siRNA transfection (72 h) on EPLIN protein expression in ARCaP~E~ cells. Right panel: effects of EPLIN siRNA transfection on the morphology of ARCaP~E~ cells. (C) Immunofluorescence staining of EPLIN and phalloidin staining of F-actin in ARCaP~E~ cells transfected with EPLIN or control siRNA for 72 h. (D) Effects of EPLIN siRNA transfection on the *in vitro* migration (left panel) and invasion (right panel) in ARCaP~E~ cells. The assays were performed at 18 h following cell seeding. Bars denote the standard error (n=3).](nihms-290940-f0001){#F1}

![EPLIN depletion inhibits E-cadherin expression, activates β-catenin signaling, suppresses proliferation and enhances chemoresistance\
(A) Comparison of the morphology of ARCaP~E~ cells stably expressing EPLIN shRNA (ARCaP~E~-shRNA, clone\#102) or control pRS (ARCaP~E~-pRS) constructs. (B) Effects of EPLIN depletion on the expression of EMT markers (E-cadherin and vimentin, left panel), nuclear translocation of β-catenin (central panel), and TCF promoter activity (right panel) in ARCaP~E~ cells. Bars denote the standard error (n=3). (C) Effects of EPLIN depletion on the actin cytoskeleton and membrane E-cadherin expression in ARCaP~E~ cells. (D) Proliferation of ARCaP~E~-shRNA cells and control cells. Bars denote the standard error (n=6). (E) Cell cycle profiles of ARCaP~E-~shRNA and control cells at 48 h and 96 h following cell seeding. *Y*-axis: cell numbers. (F) Effects of EPLIN depletion on the chemoresistance to docetaxel and Doxorubicin in ARCaP~E~ cells, as analyzed by MTT assays.](nihms-290940-f0002){#F2}

![EPLIN downregulation activates multiple pro-EMT genes\
(A) Microarray analysis of gene expression profile in ARCaP~E~-pRS and ARCaP~E~-shRNA cells. (B) Selected genes affected by EPLIN depletion in ARCaP~E~ cells. (C) Validation of several putative EPLIN target genes. Left panel: RT-PCR analysis of the effects of EPLIN depletion on the expression of several selected genes in ARCaP~E~ cells. Right panel: Western blot analysis of the effects of EPLIN depletion on protein expression in the total lysates (top) and nuclear extracts (bottom) in ARCaP~E~ cells. (D) Effects of EPLIN depletion on the expression of active MMP-27 in ARCaP~E~ cells, as analyzed by gelatin zymogram. (E) Effects of EPLIN depletion on the membrane expression of CD44 in ARCaP~E~ cells, as analyzed by fluorescence-activated Cell Sorting (FACS). *Y*-axis: cell numbers. (F) Real-time qPCR analysis of the effects of EPLIN depletion on the expression of miR-200b, miR-429 and miR-205 in ARCaP~E~ cells.](nihms-290940-f0003){#F3}

![EPLIN downregulation correlates with PCa lymph node metastasis\
(A) Microarray data-mining of EPLIN transcript expression in primary and metastatic PCa. (B) IHC expression of EPLIN were examined in matched pairs of specimens from primary and lymph node metastatic PCa and compared for the statistical significance. Bars denote the standard error.](nihms-290940-f0004){#F4}

![EPLIN downregulation correlates with clinical lymph node metastasis in breast cancer, colorectal cancer and SCCHN\
(A) Microarray data-mining of EPLIN transcript expression in primary and metastatic colorectal cancer. IHC expression of EPLIN were examined in matched pairs of tumor tissues specimens or TMAs and compared for the statistical significance in human colorectal cancer (B), breast cancer (C) and SCCHN (D). Bars denote the standard error.](nihms-290940-f0005){#F5}

![A proposed model for the role of EPLIN in PCa EMT and metastasis\
Epithelial-like, low-invasive cancer cells (such as ARCaP~E~) are joined by adherens junctions mediated by E-cadherin. The cytoplasmic tails of cadherin dimers bind to intracellular β-catenin. α-catenin binds to β-catenin, and is linked with actin filaments *via* EPLIN. EPLIN downregulation results in the disintegration of adherens junctions, remodeling of the actin cytoskeleton and activation of β-catenin signaling, which may further lead to the activation of multiple pro-EMT and -metastasis genes. These morphological, molecular and cellular alterations may significantly contribute to EMT and increase the invasiveness of PCa cells.](nihms-290940-f0006){#F6}
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Quantitative proteomic analysis of protein expression in PCa cells

  A. Report statistics of cICAT proteomics in ARCaP~E~ and ARCaP~M~ cells (2338 total spectra):                                                           
  ---------------------------------------------------------------------------------------------------------------------------- ----- ------ ------ ------ ------
  \>99 (2.0)                                                                                                                   160   804    798    1823   78.0
  \>95 (1.3)                                                                                                                   343   1607   998    2178   93.2
  \>66 (0.47)                                                                                                                  458   2064   1121   2319   99.2
  **Report Parameters:** ProtScore threshold: 1.20; Show competitor proteins within ProtScore: 1.20; Software version: 1.0.2                              

  B. Proteins significantly altered in ARCaP~E~ and ARCaPM cells                                                                                                
  ---------------------------------------------------------------- -------------------------------------------------------------------------------------------- --------
  ***Increased expression***                                                                                                                                    
  IPI00103355.1                                                    Cytochrome P450 2F1                                                                          2.0225
  IPI00418471.5                                                    Vimentin                                                                                     1.8046
  IPI00418169.3                                                    annexin A2 isoform 1                                                                         1.6253
  IPI00220327.2                                                    Keratin, type II cytoskeletal 1                                                              1.5625
  IPI00556038.2                                                    CDNA FLJ20203 fis, clone COLF1334                                                            1.4706
  IPI00014537.3                                                    Isoform 1 of Calumenin precursor                                                             1.4183
  IPI00013991.1                                                    Isoform 1 of Tropomyosin beta chain                                                          1.3734
  IPI00550766.1                                                    NNP-1 protein                                                                                1.3666
  IPI00376215.2                                                    Isoform 2 of DNA-dependent protein kinase catalytic subunit                                  1.3567
  IPI00414264.2                                                    sorcin isoform b                                                                             1.3444
  IPI00171152.1                                                    abhydrolase domain containing 11 isoform 2                                                   1.3379
  IPI00217468.2                                                    Histone H1.5                                                                                 1.315
  IPI00018349.5                                                    DNA replication licensing factor MCM4                                                        1.3106
  IPI00183695.8                                                    Protein S100-A10                                                                             1.3048
  IPI00398585.5                                                    Isoform 2 of Hook homolog 2                                                                  1.3004
  IPI00025491.1                                                    Eukaryotic initiation factor 4A-I                                                            1.2984
  IPI00741886.2                                                    PREDICTED: similar to HLA class II histocompatibility antigen, DRB1-1 beta chain precursor   1.2858
  IPI00157351.3                                                    OTTHUMP00000045700                                                                           1.2857
  IPI00009901.1                                                    Nuclear transport factor 2                                                                   1.2782
  IPI00003362.2                                                    Hypothetical protein                                                                         1.2753
  IPI00797917.1                                                    26 kDa protein                                                                               1.263
  IPI00220766.3                                                    Lactoylglutathione lyase                                                                     1.2527
  IPI00025512.2                                                    Heat-shock protein beta-1                                                                    1.2498
  IPI00023006.1                                                    Actin, alpha cardiac muscle 1                                                                1.2437
  IPI00478970.1                                                    Hypothetical protein MGC16372                                                                1.2418
  IPI00029048.2                                                    Tubulin\--tyrosine ligase-like protein 12                                                    1.2403
  IPI00029744.1                                                    Single-stranded DNA-binding protein, mitochondrial precursor                                 1.2339
  IPI00009904.1                                                    Protein disulfide-isomerase A4 precursor                                                     1.23
  IPI00220301.4                                                    Peroxiredoxin-6                                                                              1.2163
  IPI00791157.1                                                    16 kDa protein                                                                               1.2157
  IPI00216691.4                                                    Profilin-1                                                                                   1.2029
  ***Decreased expression***                                                                                                                                    
  IPI00019205.1                                                    Protein C14orf4                                                                              0.1028
  IPI00218130.2                                                    Glycogen phosphorylase, muscle form                                                          0.2191
  IPI00008918.1                                                    Isoform Beta of LIM domain and actin-binding protein 1; EPLIN-Beta                           0.2218
  IPI00384897.3                                                    PREDICTED: similar to Mucin-5B precursor                                                     0.2543
  IPI00032313.1                                                    Protein S100-A4                                                                              0.5059
  IPI00003110.2                                                    Growth factor independence-1B                                                                0.5779
  IPI00744835.1                                                    Isoform Sap-mu-9 of Proactivator polypeptide precursor                                       0.5838
  IPI00291809.4                                                    PREDICTED: similar to ankyrin repeat domain 24                                               0.6056
  IPI00219757.12                                                   Glutathione S-transferase P                                                                  0.6144
  IPI00218914.4                                                    Retinal dehydrogenase 1                                                                      0.6313
  IPI00030154.1                                                    Proteasome activator complex subunit 1                                                       0.6323
  IPI00789310.1                                                    37 kDa protein                                                                               0.6374
  IPI00797038.1                                                    mitochondrial phosphoenolpyruvate carboxykinase 2 isoform 1 precursor                        0.6586
  IPI00746205.1                                                    proteasome activator subunit 2                                                               0.6848
  IPI00747047.1                                                    Treacle major isoform                                                                        0.6892
  IPI00418790.2                                                    echinoderm microtubule associated protein like 5                                             0.694
  IPI00514204.3                                                    Lamin A/C                                                                                    0.7052
  IPI00215911.2                                                    DNA-(apurinic or apyrimidinic site) lyase                                                    0.7139
  IPI00017297.1                                                    Matrin-3                                                                                     0.7177
  IPI00784347.1                                                    Keratin, type I cytoskeletal 18                                                              0.7218
  IPI00472448.1                                                    Isoform 1 of HLA class I histocompatibility antigen, A-11 alpha chain precursor              0.7227
  IPI00554648.2                                                    Keratin, type II cytoskeletal 8                                                              0.7258
  IPI00018755.1                                                    High mobility group protein 1-like 10                                                        0.726
  IPI00017510.3                                                    Cytochrome c oxidase subunit 2                                                               0.7319
  IPI00007752.1                                                    Tubulin beta-2C chain                                                                        0.7489
  IPI00794319.1                                                    9 kDa protein                                                                                0.7515
  IPI00337544.7                                                    phosphodiesterase 4D interacting protein isoform 5                                           0.7561
  IPI00303476.1                                                    ATP synthase subunit beta, mitochondrial precursor                                           0.7733
  IPI00292387.5                                                    Isoform Alpha of Nucleolar phosphoprotein p130                                               0.7842
  IPI00024920.1                                                    ATP synthase delta chain, mitochondrial precursor                                            0.7913
  IPI00550020.2                                                    Parathymosin                                                                                 0.7927
  IPI00647118.1                                                    14 kDa protein                                                                               0.8043
  IPI00007765.5                                                    Stress-70 protein, mitochondrial precursor                                                   0.8068
  IPI00549248.4                                                    Isoform 1 of Nucleophosmin                                                                   0.8094
  IPI00020984.1                                                    Calnexin precursor                                                                           0.8123
  IPI00000874.1                                                    Peroxiredoxin-1                                                                              0.8196
  IPI00025086.3                                                    Cytochrome c oxidase subunit 5A, mitochondrial precursor                                     0.8253
  IPI00008527.3                                                    60S acidic ribosomal protein P1                                                              0.8263
  IPI00301311.1                                                    Isoform 2 of Protein SET                                                                     0.8291
  IPI00791301.1                                                    46 kDa protein                                                                               0.8342
  IPI00218200.7                                                    B-cell receptor-associated protein 31                                                        0.8344
  IPI00075248.10                                                   Calmodulin                                                                                   0.8388
  IPI00479694.1                                                    PREDICTED: similar to 40S ribosomal protein S26                                              0.8427
  IPI00002459.4                                                    annexin VI isoform 2                                                                         0.8438
  IPI00000816.1                                                    14-3-3 protein epsilon                                                                       0.8477

Ratio: relative protein expression in ARCaP~M~*vs.* ARCaP~E~ cells

*p*\<0.05
